Fig. 2From: The efficacy and safety of anti-interleukin-6 receptor monoclonal blockade in a renal transplant patient with Castleman disease: early post-transplant outcomeClinical course after transplantation. Tapering of triple immunosuppression and sustained treatment with TCZ in an MCD transplant recipient. The IL-6 levels are currently maintained at 300–500 pg/ml, and the CRP and IgG levels are trending towards normal with no allograft rejectionBack to article page